Discover the power of Rapid NGS

Rapid next-generation sequencing (NGS) can provide a complete mutational profile across multiple genes within a single day.

With advances in workflow automation, the process from sample to report is faster, enabling clinicians to make quick, biomarker-informed decisions, potentially improving patient outcomes. 

 

 

Guideline updates support expanded, rapid molecular testing

As then number of clinically relevant biomarkers increases, traditional single-analyte testing is becoming impractical and time-consuming. Due to its efficiency in profiling many genes quickly and simultaneously, Rapid NGS testing is has become a widely used routine strategy for the molecular analysis of myeloid malignancies. 

NGS testing can help inform therapy section 

With an ever-growing section targeted therapies now available and in development for myeloid malignancies, it is becoming increasingly important to have molecular insights available as quickly as possible to inform front-line therapy selection. A recent study being presented at the 66th ASH Annual Meeting highlights the potential benefit for a patient receiving a targeted therapy when their disease features a targetable mutation. 

Join Pierantonio Russo, MD, of Eversana to learn about two large-scale cohort studies that analyzed from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients and how survival outcomes were impacted by targeted therapies for oncogenic mutations.

ash24-russo

Pierantonio Russo, MD, FCPP, FAAP, STS
Corporate Chief Medical Officer
Eversana

 

ash24-poster-1

Poster #4238: Association Between Targeted Therapy and Survival in Patients with AML

Session: 615.Acute Myeloid Leukemia: Clinical and Epidemiological: Poster III

Hematology Disease Topic & Pathways: Adult, Clinical Practice (Health Service and Quality), Therapy sequence, Treatment Consideration, Human, Population

Time & Date: Monday, December 9, 2024, 6:00 PM-8:00 PM

 

ash24-poster-2

Poster #1844: Association Between Targeted Therapy and Survival in Patients with MDS

Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I

Hematology Disease Topic & Pathways: Adult, Clinical Practice (Health Service and Quality), Therapy sequence, Treatment Consideration, Human, Population

Time & Date: Saturday, December 7, 2024, 5:30 PM-7:30 PM

Enter your information below to receive the posters at the conclusion of ASH 2024.

 

Are you a healthcare professional?

あなたは医療関係者ですか?



We've detected your location to be Japan.

Sorry, this page is not available in your area.